Ligand Pharmaceuticals, Inc. (LGND)
284.47
-4.78
(-1.65%)
USD |
NASDAQ |
Sep 11, 16:00
284.47
0.00 (0.00%)
After-Hours: 20:00
Ligand Pharmaceuticals Price to Book Value : 5.857 for Sept. 11, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 5.857 |
| September 10, 2026 | 5.955 |
| September 09, 2026 | 5.931 |
| September 08, 2026 | 5.947 |
| September 04, 2026 | 5.880 |
| September 03, 2026 | 5.965 |
| September 02, 2026 | 5.907 |
| September 01, 2026 | 5.853 |
| August 31, 2026 | 5.849 |
| August 28, 2026 | 5.775 |
| August 27, 2026 | 5.858 |
| August 26, 2026 | 5.926 |
| August 25, 2026 | 5.800 |
| August 24, 2026 | 5.769 |
| August 21, 2026 | 5.894 |
| August 20, 2026 | 5.917 |
| August 19, 2026 | 5.985 |
| August 18, 2026 | 5.921 |
| August 17, 2026 | 6.007 |
| August 14, 2026 | 6.065 |
| August 13, 2026 | 5.946 |
| August 12, 2026 | 6.038 |
| August 11, 2026 | 5.945 |
| August 10, 2026 | 6.088 |
| August 07, 2026 | 6.036 |
| Date | Value |
|---|---|
| August 06, 2026 | 6.180 |
| August 05, 2026 | 6.230 |
| August 04, 2026 | 6.193 |
| August 03, 2026 | 6.013 |
| July 31, 2026 | 5.920 |
| July 30, 2026 | 6.100 |
| July 29, 2026 | 5.930 |
| July 28, 2026 | 6.100 |
| July 27, 2026 | 6.125 |
| July 24, 2026 | 6.188 |
| July 23, 2026 | 6.221 |
| July 22, 2026 | 6.264 |
| July 21, 2026 | 6.289 |
| July 20, 2026 | 6.053 |
| July 17, 2026 | 6.246 |
| July 16, 2026 | 6.104 |
| July 15, 2026 | 6.100 |
| July 14, 2026 | 6.197 |
| July 13, 2026 | 6.367 |
| July 10, 2026 | 6.511 |
| July 09, 2026 | 6.642 |
| July 08, 2026 | 6.483 |
| July 07, 2026 | 6.577 |
| July 06, 2026 | 6.597 |
| July 02, 2026 | 6.579 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Johnson & Johnson | 7.527 |
| Eli Lilly & Co. | 31.01 |
| Merck & Co., Inc. | 8.473 |
| Zevra Therapeutics, Inc. | 3.274 |
| Liquidia Corp. | 30.48 |
Price to Book Value Related Metrics
| PE Ratio | 30.41 |
| PS Ratio | 20.44 |
| Price to Free Cash Flow | 49.55 |
| Price | 284.47 |
| Earnings Yield | 3.29% |
| Market Cap | 5.667B |
| Operating PE Ratio | 59.32 |
| Normalized PE Ratio | 40.42 |